Gilead Allows Generic HIV-Drug Sales in Developing Nations
This article is for subscribers only.
Gilead Sciences Inc. will allow sales of generic versions of four HIV treatments in developing countries in the first agreement between a drug company and a patent-sharing body backed by the United Nations.
The deal permits copies of Gilead’s Viread and Emtriva medicines in 111 countries, while two experimental drugs, cobicistat and elvitegravir, will be available in 102 and 99 nations, respectively, after they’re approved by regulators, the Medicines Patent Pool Foundation said today. Gilead also announced new terms under which three Indian drugmakers will make and sell versions of three treatments.